Galectin Therapeutics Inc. · NASDAQ:GALT
Galectin Therapeutics — Investor Presentation (February 2018)
21 slides from Galectin Therapeutics's investor presentation, Feb 6, 2018
Slide 1: The Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy
The Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy Supplemental Information to Corporate Presentation February 6, 2018 NASDAQ: GALT www.galectintherapeutics.com 2017 Galectin Therapeutics | NASDAQ: GALT For more information, see galectintherapeutics.com Exhibit 99.3
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,”
Slide 3: Developing Treatments Where Galectin-3 Protein is Implicated in Disease
Developing Treatments Where Galectin-3 Protein is Implicated in Disease Clinical Phase Studies With Galectin-3 Inhibitor (GR-MD-02) Combination Cancer Immunotherapy (topic of this presentation; supplemental information to January 7, 2018 Corporate Presentation) Investigator-initiated phase 1b clinic
Slide 4: Combination Cancer Immunotherapy Development Program Summary
Combination Cancer Immunotherapy Development Program Summary The vast majority of human (& experimental animal) cancers have a large increase of galectin-3 protein Galectin-3 inhibits the immune system from killing cancer cells and has other effects that allows cancers to thrive and spread to other
Slide 5: Critical Collaboration with Providence Cancer Center
Critical Collaboration with Providence Cancer Center The Earle A. Chiles Research Institute at Providence Portland Medical Center Established 1993 by Dr. Walter Urba, MD, PhD Internationally recognized team of scientists and clinicians with focus on cancer immunotherapy William L. Redmond, PhD Assoc
Slide 6: T Cell-Modulating Antibodies For Cancer Immunotherapy
T Cell-Modulating Antibodies For Cancer Immunotherapy Multiple therapies have been developed, or are in development, that stimulate the immune system to treat cancer Recent effective classes of immunotherapies are those that stimulate T cells by blocking inhibitory inputs (blocking antibodies or che
Slide 7: Galectin-3 and Cancer
Galectin-3 and Cancer Rabinovich G, Nat Rev Immunol, 2009 Gal-3 effects on cancer cells, macrophages and T-cells in the tumor microenvironment Gal-3 is produced by both tumor cells and macrophages and has multiple effects, including Reducing T cell receptor signaling thereby blocking immune effects
Slide 8: The Galectin-3 Inhibitor GR-MD-02 Appears to Augment Anti-Tumor Activity of Cancer Immunotherapies
The Galectin-3 Inhibitor GR-MD-02 Appears to Augment Anti-Tumor Activity of Cancer Immunotherapies aCTLA-4 aPD-1 aPD-L1 GR-MD-02 GR-MD-02 aOX40 A galectin-3 inhibitor such as GR-MD-02 theoretically would have synergistic effects with other immunotherapies Pre-clinical studies have shown positive eff
Slide 9: Pre-Clinical Summary: GR-MD-02 in combination with other immunotherapies
Pre-Clinical Summary: GR-MD-02 in combination with other immunotherapies, vaccines, and radiation therapy enhances efficacy in multiple tumor models GR-MD-02 boosts frequency and persistence of antigen-specific T cells in non-tumor bearing mice alone and in combination with anti-CTLA-4 GR-MD-02 in c
Slide 10: Preclinical Data Example: GR-MD-02 plus anti-OX40 antibody in MCA-205 sarcoma
Preclinical Data Example: GR-MD-02 plus anti-OX40 antibody reduces tumor growth and prolongs survival in MCA-205 sarcoma in mice The combination of GR-MD-02 with anti-OX40 markedly enhances effect on tumor growth of either agent alone The combination of GR-MD-02 with anti-OX40 statistically signific
Slide 11: Phase 1b Clinical Trials Conducted by Providence Cancer Center
Phase 1b Clinical Trials Conducted by Providence Cancer Center Galectin Inhibitor (GR-MD-02) plus Ipilimumab (Yervoy) in Patients With Metastatic Melanoma Trial initiated in 2015, enrolled 7 subjects with GR-MD-02 doses of 1 and 2 mg/kg There were no adverse events identified due to GR-MD-02 No nota
Slide 12: GR-MD-02 Plus Pembrolizumab (KEYTRUDA)
GR-MD-02 Plus Pembrolizumab (KEYTRUDA) 12 GR-MD-02 used in combination with a flat dose (200 mg) of pembrolizumab in the following patients: Metastatic melanoma with progression after other treatment including pembrolizumab alone Recurrent or metastatic HNSCC with progression after other treatment d
Slide 13: Pembrolizumab plus GR-MD-02 Patients: Cohorts and Cohort Diagnosis
Pembrolizumab plus GR-MD-02 Patients: Cohorts 1 and 2 Cohort Diagnosis Gender Age Disease Sites Prior Treatments Response 1 Melanoma Male 76 Subcutaneous (SQ), lung Surgery/IL-2/RT/oncolytic virus/Yervoy PR 1 Melanoma Female 63 SQ, muscle, lymph node (LN) Interferon/Yervoy SD→PD 1 Melanoma Female 82
Slide 14: Clinical Results of GR-MD-02 plus Pembrolizumab (KEYTRUDA)
Clinical Results of GR-MD-02 plus Pembrolizumab (KEYTRUDA) Waterfall plot of best objective clinical response post treatment (RECIST 1.1) 14 * * Head and Neck CA Response rate of 62.5% in melanoma compares favorably to best response of KEYTRUDA alone of 33%
Slide 15: CT Scan Showing Resolution of a Large Intramuscular Melanoma Deposit
CT Scan Showing Resolution of a Large Intramuscular Melanoma Deposit Baseline Day 85 15
Slide 16: Multiple PET Scan-Detected Melanoma Deposits Resolved
Multiple PET Scan-Detected Melanoma Deposits Resolved Baseline Day 169 16 Multiple tumors in legs All tumors resolved
Slide 17: Multiple PET Scan-Detected Melanoma Deposits Resolved
Multiple PET Scan-Detected Melanoma Deposits Resolved Baseline Day 169 17 Multiple tumors throughout body (red arrows) All tumors resolved: normal contrast seen in heart, kidneys and bladder
Slide 18: CT Scan Showing Resolution of a Lung Melanoma Deposit
CT Scan Showing Resolution of a Lung Melanoma Deposit Baseline Day 85
Slide 19: Extensive Laboratory Analysis of Immune Cells and Immune Molecules
Extensive Laboratory Analysis of Immune Cells and Immune Molecules The immune monitoring laboratory at EACRI (Earle A. Chiles Research Institute) performs analysis of multiple type of immune cells and immune molecules in the blood and tumors of patients before, during, and after therapy This analysi
Slide 20: Addition of GR-MD-02 to Pembrolizumab Appears Safe and Well Tolerated
Addition of GR-MD-02 to Pembrolizumab Appears Safe and Well Tolerated Pembrolizumab has significant toxicities and adverse effects on patients In the patients treated thus far with the combination of GR-MD-02 and pembrolizumab, the Principal Investigator has documented that there have been no additi
Slide 21: Summary: GR-MD-02 for Combination Cancer Immunotherapy
Summary: GR-MD-02 for Combination Cancer Immunotherapy Many combination approaches are under investigation using marketed and experimental cancer immunotherapy drugs As a galectin-3 inhibitor, GR-MD-02 represents a novel mechanism of action, differentiated from the many other drugs that are currentl
Galectin Therapeutics — Investor Presentation (February 2018) on 6ix